Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263492 · ClinicalTrials.gov registry record · Phase 2
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05263492 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 4 participants.
The verdict
NCT05263492, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05263492
The ClinicalTrials.gov registry entry for NCT05263492 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05263492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05263492 about?
NCT05263492 is a clinical study titled "Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer". Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
What is the current status of trial NCT05263492?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-04-01. Estimated completion is 2024-10-19.
What interventions are being tested in trial NCT05263492?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT05263492?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.